ERBB2 and neoplasm: Equimolar HER2-XPAT protein (2.1 mg kg−1) or unmasked HER2-TCE-induced robust and complete tumor regression within 35 d of dosing (P < 0.001 for both versus vehicle control at day 35) (Fig. 3a) in HER2-high BT-474-bearing mice.